Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.80 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.80 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.80 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.80 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | DPP4 | P27487 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.80 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.80 |
| ▸ | GAPDH | P04406 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | PI4KA | P42356 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.80 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL29796534 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Vidarabine SCHEMBL7170349 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL29397260 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL2210868 | 1.00 | P2RY2 (0.82) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL459770 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL29362201 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28296801 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL459996 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28186074 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 | |
| Adenosine SCHEMBL28240733 | 0.99 | P2RY2 (0.80) | P2RY2ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8608922-B2 | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2013-12-17 | — | — | US | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| EP-0969848-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | Clemson University (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1998030222-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | CLEMSON UNIVERSITY (US) | 1998-07-16 | — | — | WO | claimed |
| JP-62278992-A | — | — | None | — | — | JP | disclosed |
| WO-2026106968-A1 | COMPOSITIONS COMPRISING NEMATODE AMINOACYL-TRNA SYNTHETASE AND METHODS OF USING THE SAME | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250049894-A1 | TREATMENT OF NUDT2 MUTATION | UNIV GENEVE (CH) | 2025-02-13 | — | — | US | disclosed |
| US-12181435-B2 | Methionine concentration measurement method | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2024-12-31 | — | — | US | disclosed |
| EP-4408431-A1 | TREATMENT OF NUDT2 MUTATION | Université de Genève (CH) | 2024-08-07 | — | — | EP | disclosed |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-06-15 | — | — | US | disclosed |
| WO-2000003685-A2 | NITRILASE HOMOLOGS | THOMAS JEFFERSON UNIVERSITY (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0969848-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | Clemson University (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0969848-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | Clemson University (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998030222-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | CLEMSON UNIVERSITY (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998030222-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | CLEMSON UNIVERSITY (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0247819-B1 | PROCESS FOR PRODUCING DIADENOSINE TETRAPHOSPHATE AND DERIVATIVES THEREOF | UNITIKA LTD. (JP) | 1991-07-24 | — | — | EP | disclosed |
| US-4886749-A | Process for producing diadenosine tetraphosphate and derivatives thereof | UNITIKA LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| JP-S62278992-A | PRODUCTION OF DIADENOSINE-TETRAPHOSPHATE OR DERIVATIVE THEREOF | UNITIKA LTD | 1987-12-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, GLS, GLS2 | ADORA1 3853/4885ADORA3 4059/4885ADORA2A 4415/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | ADORA1 4144/4885ADORA3 4193/4885ADORA2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.